نتائج البحث - Raajit K. Rampal

تنقيح النتائج
  1. 1
    Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia

    Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia حسب Raajit K. Rampal, María E. Figueroa

    منشور في 2016
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Leukemia secondary to myeloproliferative neoplasms

    Leukemia secondary to myeloproliferative neoplasms حسب Andrew Dunbar, Raajit K. Rampal, Ross L. Levine

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy

    Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy حسب Naveen Pemmaraju, Prithviraj Bose, Raajit K. Rampal, Aaron T. Gerds, Angela Fleischman, Srđan Verstovšek

    منشور في 2023
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Highly Conserved O-Fucose Sites Have Distinct Effects on Notch1 Function

    Highly Conserved O-Fucose Sites Have Distinct Effects on Notch1 Function حسب Raajit K. Rampal, Joseph F. Arboleda‐Velásquez, Alexandra Nita-Lazar, Kenneth S. Kosik, Robert S. Haltiwanger

    منشور في 2005
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms

    DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms حسب Omar Abdel‐Wahab, Animesh Pardanani, Raajit K. Rampal, Terra L. Lasho, Ross L. Levine, Ayalew Tefferi

    منشور في 2011
    احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Lunatic Fringe, Manic Fringe, and Radical Fringe Recognize Similar Specificity Determinants in O-Fucosylated Epidermal Growth Factor-like Repeats

    Lunatic Fringe, Manic Fringe, and Radical Fringe Recognize Similar Specificity Determinants in O-Fucosylated Epidermal Growth Factor-like Repeats حسب Raajit K. Rampal, Annie S.Y. Li, Daniel J. Moloney, Stephanie A. Georgiou, Kelvin B. Luther, Aleksandra Nita‐Lazar, Robert S. Haltiwanger

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53

    Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53 حسب Bridget K. Marcellino, Ronald Hoffman, Joseph Tripodi, Min Lü, Heidi E. Kosiorek, John Mascarenhas, Raajit K. Rampal, Amylou C. Dueck, Vesna Najfeld

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis

    Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis حسب Jan Philipp Bewersdorf, Smith Giri, Rong Wang, Nikolai A. Podoltsev, Robert T. Williams, Martin S. Tallman, Raajit K. Rampal, Amer M. Zeidan, Maximilian Stahl

    منشور في 2020
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design

    Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design حسب John O. Mascarenhas, Keri Maher, Raajit K. Rampal, Prithviraj Bose, Nikolai A. Podoltsev, Junshik Hong, Yi Chai, Steve Kye, Michael Method, Claire Harrison

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Interferons in the treatment of myeloproliferative neoplasms

    Interferons in the treatment of myeloproliferative neoplasms حسب Pankit Vachhani, John O. Mascarenhas, Prithviraj Bose, Gabriela S. Hobbs, Abdulraheem Yacoub, Jeanne Palmer, Aaron T. Gerds, Lucia Masárová, Andrew Kuykendall, Raajit K. Rampal, Ruben A. Mesa, Srđan Verstovšek

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Oral idasanutlin in patients with polycythemia vera

    Oral idasanutlin in patients with polycythemia vera حسب John Mascarenhas, Min Lü, Heidi E. Kosiorek, Elizabeth Virtgaym, Lijuan Xia, Lonette Sandy, Ruben A. Mesa, Bruce Petersen, Noushin Farnoud, Vesna Najfeld, Raajit K. Rampal, Amylou C. Dueck, Ronald Hoffman

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Single-agent dabrafenib for <i>BRAF</i> <sup>V600E</sup> -mutated histiocytosis

    Single-agent dabrafenib for <i>BRAF</i> <sup>V600E</sup> -mutated histiocytosis حسب Ankush Bhatia, Gary A. Ulaner, Raajit K. Rampal, David M. Hyman, Omar Abdel‐Wahab, Benjamin H. Durham, Ahmet Doǧan, Neval Özkaya, Mario E. Lacouture, Julio Hajdenberg, Chezi Ganzel, Eli L. Diamond

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Biological drivers of clinical phenotype in myelofibrosis

    Biological drivers of clinical phenotype in myelofibrosis حسب John Mascarenhas, Hélène F.E. Gleitz, Helen T. Chifotides, Claire Harrison, Srđan Verstovšek, Alessandro M. Vannucchi, Raajit K. Rampal, Jean‐Jacques Kiladjian, William Vainchenker, Ronald Hoffman, Rebekka K. Schneider, Alan F. List

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

    Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms حسب Neha Bhagwat, Priya Koppikar, Matthew D. Keller, Sachie Marubayashi, Kaitlyn Shank, Raajit K. Rampal, Jun Qi, Maria Kleppe, Hardik J. Patel, Smit Shah, Tony Taldone, James E. Bradner, Gabriela Chiosis, Ross L. Levine

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    A Novel Prognostic Model Including Cytogenetic and Molecular Data in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis (MF)

    A Novel Prognostic Model Including Cytogenetic and Molecular Data in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis (MF) حسب Fabio P S Santos, Bartlomiej Getta, Lucia Masárová, Christopher Famulare, Jessica Schulman, Tarcila Santos Datoguia, Giulliana Ar Goncalves, Nelson Hamerschlak, Hagop M. Kantarjian, Ross L. Levine, Paulo Vidal Campregher, Raajit K. Rampal, Srđan Verstovšek

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

    Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia حسب Srđan Verstovšek, Ruben A. Mesa, Moshe Talpaz, Jean‐Jacques Kiladjian, Claire Harrison, Stephen T. Oh, Alessandro M. Vannucchi, Raajit K. Rampal, Bart L. Scott, Sarah Buckley, Adam R. Craig, Karisse Roman‐Torres, John Mascarenhas

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment

    Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment حسب Margaret K. Callahan, Raajit K. Rampal, James J. Harding, Virginia M. Klimek, Young Rock Chung, Taha Merghoub, Jedd D. Wolchok, David B. Solit, Neal Rosen, Omar Abdel‐Wahab, Ross L. Levine, Paul B. Chapman

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome

    Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome حسب Su-Jiang Zhang, Raajit K. Rampal, Taghi Manshouri, Jay Patel, Nana Yaa Mensah, Andrew Kayserian, Todd Hricik, Adriana Heguy, Cyrus V. Hedvat, Mithat Gönen, Hagop M. Kantarjian, Ross L. Levine, Omar Abdel‐Wahab, Srđan Verstovšek

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

    Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myel... حسب John Mascarenhas, Mark Heaney, Vesna Najfeld, Elizabeth O. Hexner, Omar Abdel‐Wahab, Raajit K. Rampal, Farhad Ravandi, Bruce Petersen, Gail J. Roboz, Eric J. Feldman, Nikolai A. Podoltsev, Dan Douer, Ross L. Levine, Martin S. Tallman, Ronald Hoffman

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of<i>JAK2 V617F</i>

    Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of<i>JAK2 V617F</i> حسب Brady L. Stein, Stephen T. Oh, Dmitriy Berenzon, Gabriela S. Hobbs, Marina Kremyanskaya, Raajit K. Rampal, Camille N. Abboud, Kenneth B. Adler, Mark Heaney, Elias Jabbour, Rami S. Komrokji, Alison R. Moliterno, Ellen K. Ritchie, Lawrence Rice, John Mascarenhas, Ronald Hoffman

    منشور في 2015
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: